Skyhawk Therapeutics Announces a Second Multi-Target Collaboration Agreement with Celgene to Discover and Develop Novel Small Molecules that Modulate RNA Splicing
Celgene to receive exclusive options to license a number of Skyhawk's product candidates directed to multiple high-value autoimmune disorder, oncology, and immuno-oncology targets
BioSpace is proud to present its NextGen Bio “Class of 2019,” a list of 20 up-and-coming life science companies in North America that launched no earlier than 2017.
